TMC-435350: HCV NS3/4A protease inhibitor anti-hepatitis C virus drug

Drugs of the Future

Volumn 34, Issue 7, 2009, Pages 545-553

  Davies, S ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; MESSENGER RNA; N [2 [2 (4 ISOPROPYLTHIAZOL 2 YL) 7 METHOXY 8 METHYLQUINOLIN 4 YLOXY] 5 METHYL 4,14 DIOXO 1,2,3,3A,4,5,6,7,8,9,11A,12,12A,13,14,14A HEXADECAHYDROCYCLOPENTA[C]CYCLOPROPA[G][1,6]DIAZACYCLOTETRADECIN 12A YLCARBONYL]CYCLOPROPANESULFONAMIDE; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 5B; PEGINTERFERON ALPHA2A; PROTEINASE INHIBITOR; RIBAVIRIN; TMC 435350; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG STRUCTURE; DRUG SYNTHESIS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PROTEINASE INHIBITION; REACTION ANALYSIS; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION; UNSPECIFIED SIDE EFFECT;

EID: 84930539567     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.2009.034.07.1393070     Document Type: Review

References (22)

1. Raboisson, P., De Kock, H., Rosenquist, A. et al. Structure-activity relationship study on a novel series of cyclopentane-containing macrocyclic inhibitors of the hepatitis C virus NS3/4A protease leading to the discovery of TMC435350. Bioorg Med Chem Lett 2008, 18(17): 4853-8.
2. Stokbroekx, S.C.M., Leys, C., Swinney, K.A., Wuyts, S., Horvath, A. (Tibotec Pharmaceuticals Ltd.). Polymorphic forms of a macrocyclic inhibitor of HCV. WO 2008092954.
3. Raboisson, P.J.-M.B., De Kock, H.A., Hu, L. et al. (Tibotec Pharmaceuticals Ltd.; Medivir AB). Macrocyclic inhibitors of hepatitis C virus. CA 2616580, EP 1912999, JP 2009502889, WO 2007014926.
4. Horvath, A., Depre, D.P.M., Ormerod, D.J. (Tibotec Pharmaceuticals Ltd.). Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV. WO 2008092955.
5. Rosenquist, A., Kvarntröm, I., Svensson, S.C.T., Classon, B., Samuelsson, B. Synthesis of enantiomerically pure trans-3,4-substituted cyclopentanols by enzymatic resolution. Acta Chem Scand 1992, 46: 1127-9.
6. Johansson, P.O., Bäck, M., Kvarnström, I. et al. Potent inhibitors of the hepatitis C virus NS3 protease: Use of a novel P2 cyclopentane-derived template. Bioorg Med Chem 2006, 14(15): 5136-51.
7. Llinas-Brunet, M., Bailey, M.D., Cameron, D. et al. (Boehringer Ingelheim [Canada] Ltd.). Hepatitis C inhibitor tri-peptides. CA 2338946, EP 1105413, EP 2028186, JP 2002522554, US 6323180, WO 2000009543.
8. http://www.who.int/mediacentre/factsheets/fs164/en/, Accessed July 5, 2009.
9. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 2002, 19(3): 1-46.
10. Ozaras, R., Tahan, V. Acute hepatitis C: Prevention and treatment. Expert Rev Anti Infect Ther 2009, 7(3): 351-61.
11. de Chassey, B., Navratil, V., Tafforeau, L. et al. Hepatitis C virus infection protein network. Mol Syst Biol 2008, 4: 230.
12. TMC435350-TiDP16-C201 - OPERA 1: A study of the hepatitis C virus (HCV) protease inhibitor TMC435350 or placebo administered with or without the standard of care in treatment naïve and treatment experienced patients infected with genotype 1 hepatitis C virus (NCT00561353). ClinicalTrials.gov Web site, June 28, 2009.
13. TMC435350-TiDP16-C202: A study to ossess the activity of TMC435 on hepatitis C virus in patients who have never received treatment for their hepatitis C infection (NCT00812331). ClinicalTrials.gov Web site, June 28, 2009.
14. TMC435-TiDP16-C107: This study measures the (possible) influence of TMC435 on the activity of a selected set of drug-degrading proteins by measuring the blood levels of drugs that have been taken together with TMC435 and that are known to be specifically degraded by these drug-degrading proteins (NCT00866853). ClinicalTrials.gov Web site, June 28, 2009.
15. Lin, T.I., Lenz, O., Fanning, G. et al. In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother 2009, 53(4): 1377-85.
16. Simmen, K., Lenz, O., Lin, T. et al. In vitro activity and preclinical pharmacokinetics of the HCV protease inhibitor, TMC435350. Liver Meet (Nov 2-6, Boston) 2007, Abst 1390.
17. Lin, T., Devogelaere, B., Lenz, O. et al. Inhibitory activity of TMC435350 on HCV NS3/4A proteases from genotypes 1 to 6. Liver Meet (Oct 31-Nov 4, San Francisco) 2008, Abst 1912.
18. Liang, Y., Ishida, H., Lenz, O. et al. Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroenterology 2008, 135(5): 1710-8.
19. Van't Klooster, G.A.E., Vanwelkenhuysen, I., Hooijmaijers, R. et al. Once-daily regimens of the HCV NS3/4A-protease inhibitor TMC4353S0 are predicted to provide therapeutic exposure in plasma and liver. 43rd Annu Meet Eur Assoc Study Liver (EASL) (April 23-27, Milan) 2008, Abst.
20. Simmen, K., Verloes, R., Farha, A.K. et al. Results of a phase I placebo-controlled trial in healthy volunteers to examine the safety, tolerability and pharmacokinetics of the HCV protease inhibitor TMC435350 after single and repeated dosing. Liver Meet (Nov 2-6, Boston) 2007, Abst 1318.
21. Reesink, H., Verloes, R., Farha, K.A. et al. Safety of the HCV protease inhibitor TMC435350 in healthy volunteers and safety and activity in chronic hepatitis C infected individuals: A phase I study. 43rd Annu Meet Eur Assoc Study Liver (EASL) (April 23-27, Milan) 2008, Abst.
22. Manns, M., Reesink, H., Moreno, C. et al. OPERA-1 trial: Interim analysis of safety and antiviral activity of TMC435 in treatment-naive genotype 1 HCV patients. 44th Annu Meet Eur Assoc Study Liver (EASL) (April 22-26, Copenhagen) 2009, Abst.